# Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients

Source: https://onco.cc/trials/nct06999252/  
OnCo record `nct06999252` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Fudan University, not yet recruiting.

## Summary

Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients is a phase 2, interventional study registered as NCT06999252 by Fudan University, with a registry enrolment figure of 20 participants, started 2025-07-01 and due to reach its primary completion in 2028-12-01. Interventions recorded: Rimegepant; PD-1. Conditions listed: Colon Cancer. Primary outcome: objective response rate (ORR). Colorectal eligibility wording from the registry: "Patients with histologically or cytologically confirmed locally advanced and advanced colorectal cancer that cannot be R0 resected;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06999252
- Phase: 2
- Setting: The Combination of Rimegepant and PD-1 Inhibitor in the Treatment of Liver Metastasis Colorectal Cancer
- Sponsor: Fudan University
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06999252: https://clinicaltrials.gov/study/NCT06999252

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06999252.json